Key points are not available for this paper at this time.
Among patients with moderately to severely active Crohn's disease, those receiving intravenous ustekinumab had a significantly higher rate of response than did those receiving placebo. Subcutaneous ustekinumab maintained remission in patients who had a clinical response to induction therapy. (Funded by Janssen Research and Development; ClinicalTrials.gov numbers, NCT01369329 , NCT01369342 , and NCT01369355 .).
Building similarity graph...
Analyzing shared references across papers
Loading...
William J. Sandborn
Brian G. Feagan
Paul Rutgeerts
New England Journal of Medicine
University of Washington
University of California, San Diego
University of Chicago
Building similarity graph...
Analyzing shared references across papers
Loading...
Sandborn et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69db2bcd5b363cdf1c835875 — DOI: https://doi.org/10.1056/nejmoa1215739